content_image/929996.jpg content_image/929995.jpg content_image/929997.jpg
about 1 mM to about 3 mM, about 1 mM to about 2 mM, about 2 mM to about 5 mM, about 2 mM to about 4 mM, about 2 mM to about 3 mM, about 3 mM to about 5 mM, about 3 mM to about 4 mM, or about 4 mM to about 5 mM) calcium ion (e.g., provided as calcium chloride); about 0.1 mM to about 5 mM (e.g., about 0.1 mM to about 4 mM, about 0.1 mM to about 3 mM, about 0.1 mM to about 2 mM, about 0.1 mM to about 1 mM, about 0.1 mM to about 1 mM, about 0.5 mM to about 5 mM, about 0.5 mM to about 4 mM, about 0.5 mM to about 3 mM, about 0.5 mM to about 2 mM, about 0.5 mM to about 1 mM, about 1 mM to about 5 mM, about 1 mM to about 4 mM, about 1 mM to about 3 mM, about 1 mM to about 2 mM, about 2 mM to about 5 mM, about 2 mM to about 4 mM, about 2 mM to about 3 mM, about 3 mM to about 5 mM, about 3 mM to about 4 mM, or about 4 mM to about 5 mM) magnesium ion ( e.g., provided as magnesium chloride); about 0.1 mM to about 10 mM (e.g., about 0.1 mM to about 8 mM, about 0.1 mM to about 6 mM, about 0.1 mMto about4 mM, about 0.1 mMto about 2 mM, about 0.1 mM to about 1 mM, about 0.1 mM to about 0.5 mM, about 0.5 mM to about 10 mM, about 0.5 mM to about 8 mM, about 0.5 mM to about 6 mM, about 0.5 mM to about 4 mM, about 0.5 mM to about 2 mM, about 0.5 mM to about 1 mM, about 1 mM to about 10 mM, about 1 mM to about 8 mM, about 1 mM to about 6 mM, about 1 mM to about 4 mM, about 1 mM to about 2 mM, about 2 mM to about 10 mM, about 2 mM to about 8 mM, about 2 mM to about 6 mM, about 2 mM to about 4 mM, about 4 mM to about 10 mM, about 4 mM to about 8 mM, about 4 mM to about 6 mM, about 6 mM to about 10 mM, about 6 mM to about 8 mM, or about 8 mM to about 10 mM) of a buffer (e.g., histidine or imidazole) having a pH of about 5.5 to about 6.2 (e.g., about 6.0). 

[0245] In a further embodiment, exemplary aflibercept formulations are listed in Table 1.2 below. A surfactant ( e.g. polysorbate 80) is optionally included in the formulations of table 1.2. Formulations in Table 1.2 include formulations that are buffer free, organic co-solvent free, and buffer-free and organic co-solvent-free All formulations Table 1.2 con› tain 40 mg/mL aflibercept. In one embodiment, Captisol, if present in the formulation, is present at about 0.1 % to about 2% w/v. In another embodiment, CaC1$_{2}$ , if present in the formulation, is present at about 1 to about 10 mM. In still another embodiment, hydroxypropyl-beta-cyclodextrin (HP-beta-CD), if present in the formulation, is present at about 0.1 % to about 2% w/v. In another embodiment, human serum albumin (HSA), if present in the formulation, is present at about 0.01 % to about 2% w/v. 

<img src='content_image/929996.jpg'>

<img src='content_image/929995.jpg'>

<img src='content_image/929997.jpg'>

[0246] In one embodiment, stable formulations comprise aflibercept and low concentration of specific salts ( calcium chloride, magnesium chloride and potassium chloride) within the range present in human vitreous humor. In a further embodiment, the formulation comprises a stabilizer such as a sugar (e.g. sucrose) or Human Serum Albumin (e.g. recombinant HAS). In another embodiment, the for› mulation is free of an organic co-solvent. The use of rHSA is the most common protein found in human plasma and is known for ligand binding and colloidal stabilization, prop› erties that are also ideal for the stabilization of proteins and other biologics. In addition, because rHSA is a natural protein in the body, it is safer than alternative surfactant excipients, such as synthetic polymers, because it has a low risk for immunogenicity and there is a natural pathway for its elimination from the body. 

[0247] In a further embodiment, exemplary aflibercept formulations are listed in Table 1.3 below. Formulations in Table 1.3 include formulations that are buffer free, organic co-solvent free, and buffer-free and organic co-solvent-free. All formulations Table 1.3 contain 40 mg/mL aflibercept. 

